MEASLES VACCINATION USING MVVAC2

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 麻疹病毒(MV)是一种自然的人类病原体，但几种亚洲猕猴和其他一些非人类灵长类动物都是易感的。麻疹的发病机制与恒河猴和食蟹猴的发病机制非常相似。MV感染和疾病可在灵长类群体中广泛传播，具有显著的死亡率。包括中国人民解放军在内的几个灵长类动物中心已经使用定期、每年一次的麻疹疫苗接种，以保护易感物种免受人类传入的麻疹的影响。这一政策多年来一直有效，但目前已成功使用的麻疹或犬瘟疫苗已被淘汰。在过去的三年里，中国一直没有为灵长类动物接种麻疹疫苗。我们已经测试了一种分子克隆的麻疹疫苗毒株，它来自一瓶我们命名为MVvac2的Morten株麻疹疫苗。该病毒感染恒河猴的致病机理减弱，并保护猕猴免受病原性MV攻击。该疫苗病毒可在Vero细胞中生长，滴度可达105-106组织培养感染量/毫升，是一种实用的灵长类菌落管理疫苗。疫苗库存可以大量生产(100剂)，并在使用前立即解冻的等量冷冻保存。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Measles virus (MV) is a natural human pathogen, but several species of Asian macaque and some other nonhuman primates are susceptible. The pathogenesis of measles is modeled very closely in rhesus and cynomolgus macaques. MV infection and disease, with significant mortality, can be widespread in primate colonies. Several primate centers, including the CNPRC, have used regular, annual measles vaccination to protect susceptible species from measles introduced by humans. This policy has been effective for many years; but currently, the measles or canine distemper vaccines that have been used successfully have been taken off the market. There has been no measles vaccination of primates at the CNPRC for the last 3 years. We have tested a molecularly cloned measles vaccine strain, derived from a vial of the Moraten strain measles vaccine, which we designate MVvac2. This virus infects rhesus monkeys with an attenuated pathogenesis, and the monkeys are protected from pathogenic MV challenge. This vaccine virus can be grown in Vero cells to titers of 105 - 106 tissue culture infectious doses per ml, thus it would be a practical vaccine for primate colony management. Vaccine stocks could be produced in large volume ( 100 doses) and cryopreserevd in aliquots that would be thawed immediately before use.